San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Trefoil Therapeutics is raising $12,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Eveleth played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Trefoil Therapeutics
Trefoil is a biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which are debilitating and cause a significant amount of preventable blindness throughout the world. Lead candidate TTHX1114 is an engineered form of FGF-1 designed to stimulate proliferation and migration of corneal endothelial cells. It is initially being developed as an intracameral injection as the first pharmacologic treatment for back of the cornea surface disease (endothelial dystrophy), the leading cause of cornea transplantation surgeries. Trefoils second development program focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision.

To learn more about Trefoil Therapeutics, visit http://www.trefoiltherapeutics.com/

Contact:
David Eveleth, Chief Executive Officer
917-628-8502
develeth@trefoiltherapeutics.com
https://www.linkedin.com/in/david-eveleth-6407ba1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved